Introduction

Large numbers of patients now survive long term following stem cell transplantation (SCT). The late clinical effects of SCT are thus of major concern in the 21st century. Secondary malignant diseases are of particular clinical concern as more patients survive the early phase after transplantation and remain free of their original disease.1,2 These malignant complications have been previously reviewed in Blood3 and recently updated.4 Nonmalignant late effects are heterogeneous, and although often not life threatening they significantly impair the quality of life of long-term survivors.5 The main aims of this review by the Late Effects Working Party of the European Study Group for Blood and Marrow Transplantation (EBMT) are to present physicians with an overview of these nonmalignant late complications and provide some recommendations regarding their prevention and early treatment. The major risk factors for nonmalignant complications after SCT are chronic graft-versus-host disease (cGVHD) and/or its treatment and the use of irradiation in the pretransplantation conditioning. The interrelationship between cGVHD, total body irradiation (TBI), and nonmalignant late effects are summarized in Figure 1.

Fig. 1.

Interrelationship between total body irradiation, chronic graft-versus-host disease in the genesis of late complications after allogeneic stem-cell transplantation.

Fig. 1.

Interrelationship between total body irradiation, chronic graft-versus-host disease in the genesis of late complications after allogeneic stem-cell transplantation.

Chronic GVHD, late infections, and immune deficiency

Chronic GVHD, and its associated immune-deficiency state, is the prime cause of transplant-related mortality late after marrow grafting and contributes directly or indirectly to most nonmalignant complications. Because cGVHD has recently been reviewed in Blood,6only the main points relating to nonmalignant complications will be highlighted here. Following HLA-identical marrow transplantation, the 5-year probability of transplant-related mortality following discharge is more than 20% in patients with and around 5% in patients without chronic GVHD.7 Despite the advent of new treatment modalities, the incidence of cGVHD is being sustained by changes in clinical SCT practice as follows: (1) the expanded use of matched unrelated as well as mismatched related donors,6,8,9 (2) the increasing use of SCT in older patients, (3) the increasing use of donor lymphocyte infusions to treat relapsed disease or to achieve full donor chimerism after nonmyeloablative transplantation, and (4) current evidence that suggests patients receiving allogeneic peripheral blood stem cell transplants have an equally high or a higher incidence of chronic GVHD compared with patients receiving marrow grafts. Long-term follow-up data from Seattle indicated that, although the cumulative incidence of chronic GVHD at 3 years was similar in patients whose stem cells came from marrow versus peripheral blood, cGVHD after peripheral blood SCT was more protracted and less responsive to treatment than cGVHD after marrow SCT.10 

Whereas the prophylactic use of multiagent immunosuppression has reduced the incidence and severity of acute GVHD, the incidence of chronic GVHD remains unchanged. The incidence of chronic GVHD after sibling-matched related, unrelated, and peripheral blood stem cell transplantation lies between 27% to 50%, 42% to 72%, and 54% to 57%, respectively.11 Factors that increase the development of chronic GVHD include increased donor and recipient age, prior acute GVHD, use of alloimmune female donors, type of GVHD prophylaxis, and history of recipient herpes virus infection. There are several grading schemes that predict survival of patients with chronic GVHD. In these grading schemes, poor prognostic variables include lichenoid skin changes, extensive skin involvement (> 50% body surface area), elevated bilirubin, progressive onset, thrombocytopenia, and prior steroid refractory/dependent acute GVHD (reviewed in Lee et al11).

Immune reconstitution has a pivotal role in the long-term issue of allogeneic SCT. Several studies have characterized the immune reconstitution in the few months following allogeneic SCT, but data on long-term immune reconstitution involving large numbers of patients are scarce.12-15 A large number of variables related to patient or transplant characteristics, such as age of recipients, stem cell engineering, type and duration of their disease, or conditioning regimen, may influence the recovery of immunity after SCT. Other posttransplantation variables, and in particular chronic GVHD and the consequent administration of immunosuppressive drugs, also have an effect. Chronic GVHD is the major factor affecting immune reconstitution of B cells and CD4 and CD8 T cells. Donor source (marrow versus peripheral blood), unrelated versus sibling transplant, and the degree of HLA compatibility between donor and recipient also affect the pace of immune reconstitution. Low B-cell count, inverted CD4/CD8 ratio, and a decreased immunoglobulin A (IgA) level are all risk factors associated with late infections. The role of slow B-cell reconstitution on the susceptibility to infections occurring in the years following SCT has been pointed out in 2 recent studies.12,14 Factors contributing to the immune deficiency post-SCT are summarized in Figure2. Recent immunologic methods such as repertoire analysis or the identification of recent thymic emigrants are currently being used as tools to evaluate immune reconstitution following SCT. Using these new tools, it has recently been suggested15 that the immune system could regain normal functioning in the long term post-SCT. However, because most of the patients in the latter study were treated for severe aplastic anemia and did not have cGVHD,15 it still remains to be proven whether leukemic survivors who have undergone TBI-conditioned SCT and developed cGVHD are also able to recover normal immune function 15 to 20 years post-SCT.

Fig. 2.

Factors contributing to late immune deficiency and late infection following allogeneic stem cell transplantation.

Fig. 2.

Factors contributing to late immune deficiency and late infection following allogeneic stem cell transplantation.

Late bacterial and viral infections have been extensively reviewed, and guidelines for preventing and treating these opportunistic infections after SCT are proposed in a document published under the hospice of the Centers for Disease Control and Prevention (CDC), the Infectious Disease Society of America, and the American Society of Blood and Marrow Transplantation.16 Susceptibility to encapsulated bacteria (Streptococcus pneumoniae, Haemophilus influenzae, and Neisseria meningitidis) has been well documented, especially in patients with current or previous chronic GVHD. Late (> 2 years) fungal or cytomegalovirus (CMV) infections are rare and almost invariably occur in patients with ongoing immune suppression for GVHD. Varicella-zoster, in contrast, is extremely frequent even in patients without GVHD, but it usually occurs within several months of SCT after acyclovir prophylaxis has been discontinued. Finally, of the parasitic infections, latePneumocystis carinii pneumonia (PCP) andToxoplasma gondii infections are more common in patients receiving active treatment for cGVHD. Because PCP prophylaxis with trimethoprim-sulfamethoxazole is highly active, this regimen should be given to all patients receiving treatment for cGVHD and/or those with CD4+ cells less than 0.2 × 109/L. Probably, PCP prophylaxis should be continued for several weeks after the cessation of immunosuppressive therapy given the long-lasting T-cell defects characteristic of patients who have developed cGVHD.

Late ocular effects

Ocular complications of the posterior segment

These complications can be divided into microvascular retinopathy, optic disk edema, hemorrhagic complications, and infectious retinitis.17 Fungal infections typically occur within 120 days of SCT, whereas herpes zoster, CMV, and toxoplasmic retinitis occur later. Ischemic retinopathy with cotton-wool spots and optic-disk edema has been described in 10% of patients following SCT.18-20 Microvascular retinopathy occurs mainly after TBI-conditioned allogeneic SCT in patients receiving cyclosporine as GVHD prophylaxis. Visual acuity is decreased in most patients but recovers when cyclosporine is withdrawn. Atypical retinal microvasculopathy, without cotton-wool spots, has also been described.21 Radiation may provoke an occlusive microangiopathy but only if the radiation dose exceeds 35 Gy. Thus, TBI alone cannot explain ischemic retinopathy in patients who have received a transplant, and additional factors, such as cyclosporine, may lower the threshold for radiation retinopathy.22 Ischemic retinopathy has been reported in patients conditioned with busulfan and cyclophosphamide without irradiation,23 or in patients receiving Campath-1G for GVHD prophylaxis.24 In most cases, retinal lesions resolve with withdrawal or reduction of immunosuppressive therapy, and resolution has even been described in a case associated with complete blindness.25 Although ischemic retinopathy is still an enigma, these data suggest that the development of ischemic eye lesions is a multifactorial process leading to capillary damage of the eye fundus. These endothelial changes might not be restricted to the eye but may reflect a generalized process within the microvasculature.

Ocular complications of the anterior segment

The 2 most common late complications affecting the anterior segment are cataract formation and keratoconjunctivitis sicca syndrome. Cataract formation, particularly posterior subcapsular cataracts, has long been recognized in recipients of SC transplant as one of the most frequent late complications of TBI.26,27 After single-dose TBI almost all patients develop cataracts within 3 to 4 years, and most if not all need surgical repair. Although the probability of developing cataracts after fractionated TBI lies around 30% at 3 years, the incidence may reach more than 80% in 6 to 10 years post-SCT27,28 (Table 1; Figure3A). In a multivariate analysis, the use of TBI, fractionation of its dose (Figure 3B), and the use of steroid treatment for longer than 3 months were associated with a significant risk of cataract development.27 The effect of the dose rate of irradiation on the subsequent development of cataracts is also established.29,30,32 In the largest series evaluating a cohort of 1064 patients,30 factors independently associated with an increased risk of cataracts were older age (> 23 years), higher dose rate (> 0.04Gy/minute), allogeneic SCT, and steroid administration. Finally, in prospective studies comparing cataract incidence rate and risk factors it has been shown that patients who receive cyclophosphamide and TBI (Cy/TBI) have a higher incidence of cataract formation than those treated with busulfan and cyclophosphamide (BuCy).31 Although the total dose of TBI is the most important factor for cataract formation, the incidence, severity, and time course of cataract formation differ depending on the number of fractions, dose rate of irradiation, the age of the patient, and the use of steroids. The only treatment for cataract is to surgically remove the opacified lens from the eye to restore transparency of the visual axis. Today, cataract surgery is a low-risk procedure and improves visual acuity in 95% of eyes that have no other pathology. Results of surgical repair in patients who have received a transplant are not yet available.

Table 1.

Cataract after stem cell transplantation

ReferenceType of studyPatients (N)Probability of cataract formationRemarks
sTBIfTBINo TBI
Deeg et al26 Single center (Seattle) 277 80% at 6 y 18% at 6 y 19% at 6 y Sparing effect of fTBI  
Tichelli et al27 Single center (Basel) 197 100% at 3.5 y;
surgery 96% 
29% at 3.3 y  TBI  
      Single dose 
    83% at 6 y  Corticosteroids > 3 mo 
Benyunes et al28 Single center (Seattle) 492 85% at 11 y Risk at 11 y
 50% (> 12 Gy) 
19% at 11 y Need of surgical repair
 59% sTBI 
     34% (12 Gy)   33% fTBI 
       23% no TBI 
      Highest yearly hazard of cataract
formation earlier with sTBI than fTBI  
Belkacemi et al29 Single center (Paris) 494 34% at 5 y 11% at 5 y  High dose rate, main risk factor  
Belkacemi et al30 EBMT registry 1063 Risk at 10 y 60%;
32% surgery 
Risk at 10 y 43%;
3% surgery 
—  Risk factors
 Older age 
       Higher dose rate 
       Allogeneic SCT 
       No heparin  
Socié et al31 4 randomized studies 488 —  Risk at 7 y
 AML, 12.4% 
Risk at 7 y
 AML, 12.3% 
Comparison TBI versus BuCy
Increased risk for CML patients with TBI  
     CML, 47%  CML, 16%  
ReferenceType of studyPatients (N)Probability of cataract formationRemarks
sTBIfTBINo TBI
Deeg et al26 Single center (Seattle) 277 80% at 6 y 18% at 6 y 19% at 6 y Sparing effect of fTBI  
Tichelli et al27 Single center (Basel) 197 100% at 3.5 y;
surgery 96% 
29% at 3.3 y  TBI  
      Single dose 
    83% at 6 y  Corticosteroids > 3 mo 
Benyunes et al28 Single center (Seattle) 492 85% at 11 y Risk at 11 y
 50% (> 12 Gy) 
19% at 11 y Need of surgical repair
 59% sTBI 
     34% (12 Gy)   33% fTBI 
       23% no TBI 
      Highest yearly hazard of cataract
formation earlier with sTBI than fTBI  
Belkacemi et al29 Single center (Paris) 494 34% at 5 y 11% at 5 y  High dose rate, main risk factor  
Belkacemi et al30 EBMT registry 1063 Risk at 10 y 60%;
32% surgery 
Risk at 10 y 43%;
3% surgery 
—  Risk factors
 Older age 
       Higher dose rate 
       Allogeneic SCT 
       No heparin  
Socié et al31 4 randomized studies 488 —  Risk at 7 y
 AML, 12.4% 
Risk at 7 y
 AML, 12.3% 
Comparison TBI versus BuCy
Increased risk for CML patients with TBI  
     CML, 47%  CML, 16%  

TBI indicates total body irradiation; sTBI, single-dose TBI; fTBI, fractionated TBI; BuCy, conditioning with busulfan/cyclophosphamide; Gy, Gray; —, not applicable.

Fig. 3.

Cataract formation after TBI.

(A) Cataract formation occurs earlier after single dose than after fractionated dose total body irradiation (reprinted from Tichelli et al27 with permission). (B) Fractionated TBI is associated with a significant, dose-dependent risk of cataract formation (reprinted from Benyunes et al28 with permission, nonexclusive world English rights only).

Fig. 3.

Cataract formation after TBI.

(A) Cataract formation occurs earlier after single dose than after fractionated dose total body irradiation (reprinted from Tichelli et al27 with permission). (B) Fractionated TBI is associated with a significant, dose-dependent risk of cataract formation (reprinted from Benyunes et al28 with permission, nonexclusive world English rights only).

Keratoconjunctivitis sicca syndrome is usually part of a more general syndrome with xerostomia, vaginitis, and dryness of the skin.33 All these manifestations are closely related to cGVHD34 that may lead in its most extensive forms to a Sjögrenlike syndrome.35 The ocular manifestations include reduced tear flow, keratoconjunctivitis sicca, sterile conjunctivitis, corneal epithelial defects, and corneal ulceration.36-40 The incidence of late-onset keratoconjunctivitis sicca syndrome may reach 20% in 15 years after SCT41-43 but reaches nearly 40% in patients with cGVHD, compared with less than 10% in those without GVHD. Risk factors for late-onset keratoconjunctivitis include cGVHD, female sex, age older than 20 years, single-dose TBI, and the use of methotrexate for GVHD prophylaxis.41 Treatment is based on the management of cGVHD with repeated use of topical lubricants. Topical corticosteroids may improve symptoms but can cause sight-threatening complications if used inappropriately in herpes simplex virus or bacterial keratitis. Topical retinoic acid may also be used.44 

Pulmonary late effects

Significant late toxicity involving both the airways and lung parenchyma affects at least 15% to 40% of patients after SCT. Most of the studies have been performed in adult patients, and results are still conflicting because of varying selection and evaluation criteria, limited sample size, and short follow-up. Moreover, clinical syndromes are not well defined or definable because of overlapping mechanisms and/or because they represent a continuum rather than a distinct disorder. Sensitivity to cytotoxic agents and irradiation, infections, and immune-mediated lung injury associated with GVHD are the most prominent factors that contribute to late respiratory complications.45 Impaired growth of both lung and chest can be an additional factor in children.

Restrictive lung disease

Abnormal pulmonary function tests (PFTs) with loss of lung volume and diffusing capacity may exist prior to SCT as a result of the intensification of front-line treatment.46 Although the relevance of pretransplantation PFTs is still debated, some studies indicate that PFTs can be predictive of complications and outcome after SCT and should, therefore, be included within the pretransplantation investigation program.47-49 Restrictive lung disease is frequently observed 3 to 6 months after SCT in patients conditioned with TBI and/or receiving an allogeneic SCT, but in most cases it is not symptomatic. Restrictive disease is often stable and may recover, partially or completely, within 2 years.46,50,51 However, some patients do develop severe late restrictive defects and may eventually die of respiratory failure.52 

Chronic obstructive lung disease

Chronic obstructive pulmonary disease with reduced forced expiratory volume in 1 second/forced vital capacity (FEV1/FVC) and FEV1 can be detected in up to 20% of long-term survivors after SCT.53-55 Its pathogenesis is not yet well understood. It has been mainly associated with cGVHD, but other potential risk factors, including TBI, hypogammaglobulinemia, GVHD prophylaxis with methotrexate, and infections, have been described. Although direct immune-mediated damage by donor T lymphocytes and cytokines is classically the main mechanism, airflow obstruction can also be due to indirect consequences of cGVHD, for example aspiration secondary to esophageal GVHD, sicca syndrome, abnormal mucociliary transport,56 and recurrent infections. Mortality is high among these patients, particularly in those with an earlier onset and rapid decline of FEV1. Symptoms consist of nonproductive cough, wheezing, and dyspnea; chest radiography is normal in most cases. High-resolution computed tomography (CT) scanning may reveal nonspecific abnormalities.57 Symptomatic relief can be obtained in some patients with bronchodilators; however, in most cases obstructive abnormalities are not improved by this treatment. Patients with low IgG and IgA levels should receive immunoglobulins to prevent infections, which may further damage the airways. Immunosuppressive therapy may be of benefit, but typically improvements occur in less than 50% of cases probably because the damage has already become irreversible or because other pathogenetic factors persist. Asymptomatic patients with abnormal PFTs should be closely monitored for the development of respiratory symptoms; an early recognition of airflow obstruction allows the initiation of treatment at a potentially reversible stage.

Obliterative bronchiolitis (OB), the best characterized obstructive syndrome, has been reported in 2% to 14% of allogeneic SC transplant recipients and carries a mortality rate of 50%.56,58-61OB is strongly associated with cGVHD and low levels of immunoglobulins. GVHD is probably responsible for the initial epithelial injury to the small airways62 with further damage caused by repeated infections. Initial symptoms often resemble those of recurrent upper respiratory tract infections, and then persistent cough, wheezing, inspiratory rales, and dyspnea appear. PFTs gradually deteriorate with severe and nonreversible obstructive abnormalities. Chest radiographs and CT scanning may reveal hyperinflation with or without infiltrates and vascular attenuation; however, radiologic findings do not correlate with lung function changes probably because of the patchy nature of the disease.63 Bronchoscopy with transbronchial biopsy can help to rule out infection and may reveal obliteration of bronchioles with granulation tissue, mononuclear cell infiltration, or fibrosis. It is not clear to what extent combined immunosuppressive treatment can be effective in the treatment of this disease, which typically does not respond to treatment with steroids. Azathioprine and mycophenolate may lead to improved symptoms in some cases. Prophylaxis and prompt treatment of infections are the most important elements of clinical management and may help to alter the clinical course of a disease whose pace can vary from slow progression to rapidly fatal respiratory failure. Single or double lung transplantation has been suggested for patients with advanced disease,64 although the transplanted lung may also be a target for immune-mediated damage.

Late liver complications

Unraveling the cause of liver dysfunction can pose difficulties, first, because several causes of liver disease may coexist and, second, because patterns of viral serology may be atypical. Furthermore, in addition to the most important hepatotropic viruses, other agents, like herpesviruses (including CMV), adenoviruses, and Epstein-Barr virus, may be implicated, sometimes leading to life-threatening fulminant hepatitis.65 Useful tools for differential diagnosis are timing posttransplantation, type of clinical and biochemical deterioration, previous evidence of liver complications, including veno-occlusive disease (VOD), acute or chronic GVHD, and infection. Liver biopsy is often difficult to interpret, but histologic examination can be helpful in discriminating between an acute exacerbation of viral hepatitis and an episode of GVHD.

Hepatitis B and hepatitis C infections

Hepatitis B (HBV) or hepatitis C (HCV)66 may be nonsymptomatic or may progress to fulminant hepatitis or evolve to chronic active hepatitis and cirrhosis. Today, the risk of acquiring HBV and HCV infection from blood transfusion is greatly reduced. A recent prospective study of the EBMT, which included patients transfused in the “post-screening” era, showed that the prevalence of serum hepatitis B surface antigen (HBsAg)– and HCV-RNA–positive SCT patients was 3.1% and 6.0%, respectively. The prevalence of “de novo” infection in patients receiving HBsAg and HCV-RNA–negative SC transplant was 2.0% and 7.4%, respectively; the prevalence of donors positive for HBsAg and HCV-RNA, was found to be 2.6% and 3.6%, respectively.67 Chronic viral hepatitis still remains an important clinical problem in this setting.68,69 

Patients infected with HBV generally show mild to moderate liver disease on long-term follow-up, but cirrhosis as a result of chronic hepatitis B has not been reported to date. Chronic hepatitis C is often asymptomatic with fluctuating transaminases levels and no signs or symptoms of uncompensated liver disease at least during the first decade following SCT.68-70 Progression to cirrhosis or advanced liver disease in patients surviving more than 10 years does occur, however71 (G.S., unpublished observations, 2003). These observations indicate that, although the outcome of chronic hepatitis was thought to be benign, it may represent an important clinical problem in very long-term survivors. Careful tapering of immunosuppressive therapy posttransplantation, with monitoring of biochemical parameters and viral load, is crucial to prevent and allow early treatment of hepatitis reactivation. Increasing HBV viral load may need treatment with lamivudine.72However, prolonged therapy with this drug is followed by the emergence of HBV DNA polymerase mutants. As the selection of these mutants is a function of time, the indication for long-term therapy should be reviewed. The combination of lamivudine and anti-HBs immunoglobulins may also be of value. In patients with active chronic HCV, hepatitis treatment with interferon, with or without nucleotide analogues, is indicated.73 

Iron overload

On the basis of serum ferritin levels, the diagnosis of iron overload can be made in up to 88% of long-term survivors of SCT.74 Prolonged dyserythropoiesis and increased iron absorption both contribute to the accumulation of iron. Liver biopsies performed early after SCT show siderosis in most patients.75 Autopsies performed in patients dying early after SCT show iron accumulation in a range equivalent to that of patients suffering from hereditary hemochromatosis.76 Iron deposition has also been demonstrated in others tissues, such as the myocardium or bone marrow.76,77 Iron overload may be associated with a number of clinical consequences, but these consequences have not been extensively evaluated in patients posttransplantation. A clear correlation exists between iron deposition and persistent hepatic dysfunction, probably as a consequence of intracellular iron accumulation and the toxic effect of free radicals. In heavily transfused patients, such as those with thalassemia, iron can contribute to hepatic fibrosis, cirrhosis, and hepatocellular carcinoma as well as to cardiac dysfunction.77,78 Hepatic iron overload may also worsen the natural course of chronic hepatitis, in particular hepatitis C, and the response to antiviral therapy.79 Finally, iron overload increases the risk of opportunistic infections in immunocompromised patients, mucormycosis being the infection most usually observed in SCT.80Although iron overload spontaneously decreases in the years following SCT,78 the true effect of iron overload on post-SCT complications such as diabetes mellitus, impotence, hypogonadism, or growth retardation has not yet been established. All survivors (even if asymptomatic) should, therefore, be assessed for iron overload by measuring serum ferritin. Iron overload should be treated by means of phlebotomy and/or chelation therapy, especially when iron overload coexists with chronic viral hepatitis. Phlebotomy has the advantage over chelation of better compliance, fewer side effects, and lower costs. The use of recombinant human erythropoietin may facilitate this strategy in patients who have low hemoglobin levels.81,82 

Late complications of bones and joints

Avascular necrosis of bone (AVN)

The published incidence of AVN varies from 4% to more than 10% in the largest series.83-87 The mean time from transplantation to AVN is 18 months (range, 4-132 months), and pain is usually the first sign. Early diagnosis can rarely be made using standard radiography alone, and magnetic resonance imaging is the investigation of choice (Figure 4). The hip is the affected site in more than 80% of cases, with bilateral involvement occurring in more than 60% cases. Other locations described include the knee (10% of patient with AVN), the wrist, and ankle. Symptomatic relief of pain and orthopedic measures to decrease the pressure on the affected joints are of value, but most adult patients with advanced damage will require surgery. The probability of total hip replacement following a diagnosis of AVN is approximately 80% at 5 years.88,89 Although short-term results of joint surgery are excellent in the majority (> 85%) of cases, it is clear that long-term follow-up of the protheses are needed in young patients who have a long life expectancy. Studies evaluating risk factors for AVN have clearly identified steroids (both total dose and duration) as the strongest risk factor. Thus, unnecessary long-term low-dose steroids for nonactive chronic GVHD should be avoided. The second major risk factor for AVN is TBI, the highest risks being associated with receipt of single doses of 10 Gy or higher or more than 12 Gy in fractionated doses.87 Finally, some underlying conditions may predispose a patient to develop AVN after SCT, in particular patients receiving transplants for severe aplastic anemia90 or acute lymphoblastic leukemia.

Fig. 4.

Avascular necrosis of the hip.

Standard radiography versus MRI as a tool for the diagnosis of avascular necrosis. These panels illustrate that standard radiography could be strictly normal at the first clinical sign while MRI is already highly abnormal. The top panel shows the normal appearance of the hip using standard radiography. The middle and bottom panels show 2 different MRI sequences showing that, although the femoral head is still spherical, the adjacent bone is already affected with necrosis, with even cartilage modification.

Fig. 4.

Avascular necrosis of the hip.

Standard radiography versus MRI as a tool for the diagnosis of avascular necrosis. These panels illustrate that standard radiography could be strictly normal at the first clinical sign while MRI is already highly abnormal. The top panel shows the normal appearance of the hip using standard radiography. The middle and bottom panels show 2 different MRI sequences showing that, although the femoral head is still spherical, the adjacent bone is already affected with necrosis, with even cartilage modification.

Osteoporosis

Hematopoietic SCT can induce bone loss and osteoporosis via the toxic effects of TBI, chemotherapy, and hypogonadism (reviewed in Weilbaecher91 and Schimmer et al92). Osteopenia and osteoporosis are both characterized by a reduced bone mass and increased susceptibility to bone fracture. These conditions are further distinguished by the degree of reduction in bone mass and can be quantified by T and Z scores on dual photon densitometry. The Z score is similar to the T score but uses mean bone mass from an age- and sex-matched control population as a reference value. The relative risk of fracture doubles for every standard deviation below the control adult peak bone mass. The incidence and clinical course of bone mineral density (BMD) abnormalities following hematopoietic SCT have been studied in 2 large series.93,94 In both, the cumulative dose and number of days of glucocorticoid therapy and the number of days of cyclosporine or tacrolimus therapy showed significant associations with loss of BMD. Nontraumatic fractures occurred in 10% of patients. These results indicate that loss of BMD after allogeneic SCT is common and is accelerated by the length of immunosuppressive therapy and cumulative dose of glucocorticoid. With the use of World Health Organization (WHO) criteria, nearly 50% of the patients have low bone density, a third have osteopenia, and roughly 10% have osteoporosis, 12 to 18 months posttransplantation. The true incidence and morbidity rate of osteoporosis in very long-term SCT survivors is currently unknown. Preventative measures of osteoporosis must include sex-hormone replacement in patients with gonadal failure; the efficacy of new treatments for osteoporosis in long-term survivors of SCT requires evaluation.

Dental late effects

Both TBI-based regimens and those without irradiation can result in severe damage to the enamel organ and developing teeth. These defects may be prolonged or permanent.95,96 After TBI in children, underdevelopment of the mandible and anomalies in the mandibular joint may also occur.96 In children, long-term clinical and radiologic follow-ups reveal hypoplasia and microdontia of the crowns of erupted permanent teeth and thinning and tapering of the roots of erupted permanent molars or incisors.97-100Caries are found more frequently in patients who have received a transplant compared with age-matched healthy children. The defects in dental elements post-SCT may occur at any age of tooth development, and only the severity seems to depend on age at SCT.

Recommendations to minimize this adverse effect aim to preserve the enamel layer and prevent, by active oral hygiene, dental plaque, periodontal and oral mucosal infections, and xerostomia, all of which contribute to the development of caries. Specialist dental consultation before SCT and yearly posttransplantation examinations should be requested to register any specific dental problems, to provide treatment, and to give instruction on oral and dental care. In the long-term, 3 key elements to reduce dental complications are brushing teeth, application of fluoride, and the use of antiseptic mouthwashes. Brushing teeth should be done twice daily, with a soft brush and fluorinated toothpaste.

Endocrine function after SCT

Thyroid dysfunction

Thyroid dysfunction has long been recognized as one of the most frequent late complications of SCT.101 The most common thyroid abnormalities can be classified into 3 distinct patterns: subclinical-compensated hypothyroidism, overt hypothyroidism, and autoimmune thyroid disease.

Subclinical-compensated hypothyroidism.

Between 7% and 15.5% of patients will develop subclinical hypothyroidism (slightly high serum thyroid-stimulating hormone [TSH] and normal free-T4 levels) in the year post-SCT.102-104 It is not yet clear if patients who develop subclinical hypothyroidism should be treated with L-thyroxin because most of these cases are mild, compensated, and may resolve spontaneously.102,105,106 Furthermore, treatment with L-thyroxin might induce early osteoporosis, especially if given to those women after SCT with gonadal failure. It is also not clear if a relationship exists between high TSH levels and carcinogenesis.107 One possible approach is to monitor TSH and free-T4 levels twice yearly and to consider L-thyroxin treatment only if TSH concentration remains high or is increasing.108 

Overt hypothyroidism.

The great majority of cases of overt hypothyroidism following SCT are due to direct damage to the thyroid gland. Secondary hypothyroidism, caused by pituitary damage, is rare following SCT. Hypothyroidism is usually diagnosed after a median period of 50 months posttransplantation. The frequency of hypothyroidism requiring L-thyroxin replacement therapy is highly variable,109,110depending to a large extent on the type of pretransplantation conditioning applied as follows: nearly 90% in patients who have received 10 Gy single-dose TBI,110 14% to 15% of patients following fractionated TBI,103 and smaller numbers after conditioning with BuCy.32,109-111 Treatment with L-thyroxin is indicated in all cases of frank hypothyroidism (elevated TSH with low free-T4 blood levels). Thyroid hormone levels should be measured 4 to 6 weeks after commencement of replacement therapy, and dosage should be tailored thereafter to the individual patient and adjusted according to thyroid function evaluation every 6 months. Elderly patients should have an electrocardiogram (ECG) prior to commencing treatment to exclude associated ischemic heart disease and/or arrhythmias.

Autoimmune thyroid disease.

Autoimmune thyroiditis, presumably transferred via donor cells, has been reported.112 This same autoimmune mechanism can also lead to hyperthyroidism if the donor is affected with Grave disease.113 

Growth

Linear growth is an intricate process that may be affected by several systems, including genetic (ie, midparental height), nutritional, hormonal, and psychological factors. Intensive anticancer therapy during childhood may influence all or some of these factors resulting in decreased growth. Children who undergo SCT form a heterogeneous group because of the different treatment protocols used. In addition, posttransplantation factors such as GVHD and its treatment, especially the use of long-term steroids, may induce growth failure in childhood.104,114-119 

Final height achievement has been reported in some studies.115-117,120-122 Decreased growth has been described in patients who underwent SCT during childhood. The mean loss of height (as estimated by the standard deviation score [SDS]) is estimated to be approximately 1 height SDS (equivalent to 6 cm) compared with both the mean height at the time of SCT and mean genetic height.115-117,120,121,123 Nevertheless, nearly 80% of the children will achieve adult height values above the 3rd percentile (or −2 height SDS) for the healthy general population.116Growth deficiency is more pronounced in children who receive transplants at a younger age (< 10 years) and in those who have received irradiation. In contrast, children who are conditioned with non-TBI regimens, such as cyclophosphamide or busulfan-cyclophosphamide, usually grow normally. Patients who have been exposed to cranial radiotherapy (CRT) prior to conditioning with TBI show a greater decline in growth.124 The role of growth hormone (GH) deficiency as a cause of growth failure and its substitution in children after SCT is still controversial. Although some reports show some benefit of GH treatment in children after SCT,125,126 others have failed to document GH deficiency.106,121,122 Furthermore, some studies have failed to demonstrate any correlation between growth rate and the GH secretion level after pharmacologic provocative tests.116,127 In a study involving children who had survived more than 5 years after SCT for severe aplastic anemia (SAA),117 the decrease in growth observed in a population of 11 children who had received thoracoabdominal irradiation in their pretransplantation conditioning was significantly higher than seen in a group of 27 children who had received cyclophosphamide only. The decrease in growth found in the irradiated group cannot be explained by impaired secretion of growth hormone because thoracoabdominal irradiation spares the hypothalamus and pituitary gland. The reduction in growth observed in the irradiated group may, however, be explained by the direct effect of irradiation on the gonads, the thyroid gland, and/or the bone epiphyses.

Puberty and gonadal failure

Gonadal failure (both testicular and ovarian) is a common long-term consequence of the chemotherapy given prior to SCT and of the pretransplantation conditioning. The major cause of gonadal damage leading to hypergonadotropic-hypogonadism is irradiation.128,129 Similar damage can also be caused by busulfan. Among patients who have received a transplant, it is uncommon to find either a condition of hypogonadotropic-hypogonadism or precocious puberty because of irradiation damage to the hypothalamic-pituitary area.120,130 

In males, the testicular germinal epithelium (Sertoli cells) where spermatogenesis occurs is more vulnerable to radiation and chemotherapy than the testicular Leydig cell component, which is involved in testosterone secretion. Therefore, testosterone levels are usually normal even when spermatogenesis is reduced or absent. The serum follicle-stimulating hormone (FSH) is typically elevated, whereas luteinizing hormone (LH) levels may remain in the normal range. The great majority of patients will not, therefore, require testosterone replacement to ensure sexual activity, libido, erection, and ejaculation. Furthermore, boys transplanted during childhood will usually spontaneously start and complete puberty. Patients transplanted before puberty, however, might achieve a reduced testicular volume as a result of damage to the germinal epithelium.131 Sex hormone replacement therapy (SHRT) with testosterone derivatives in males is indicated in patients with severe uncompensated hypogonadism.

In females, the ovaries are more vulnerable to irradiation and chemotherapy than the testes, and hypergonadotropic-hypogonadism is almost the rule. Busulfan is one of the most gonadotoxic agents, whereas cyclophosphamide is usually associated with only minor effects on gonadal function.

Prepubertal patients conditioned with cyclophosphamide alone for SAA usually have normal puberty.114 The age at transplantation is of major importance because the younger the age, the better will be the chances for gonadal recovery. In fact, ovarian failure in adult women is usually irreversible, whereas in prepubertal girls, although uncommon, there is still a greater possibility for a subsequent spontaneous recovery and achievement of spontaneous menarche.131-134 Fractionation of the irradiation reduces the effect on the ovaries114,135; girls treated with 12 Gy fractionated TBI are 5 times more likely to have a spontaneous recovery to normal ovarian function than girls receiving single-dose TBI. With the increasing utilization of BuCy in pediatric pretransplantation conditioning, it becomes clear that most girls of any age at transplantation develop ovarian failure.136,137 

Most females will need SHRT, both for the induction of puberty in girls who have had SCT prior to the menarche and for maintaining menstrual cycles and bone turnover/mineralization in adult women. In prepubertal girls who do not undergo puberty spontaneously post-SCT, estrogen treatment should be started at the age of 12 to 13 years to promote breast and uterine development and the pubertal growth spurt. The dose of estrogen treatment will need to be gradually increased, and a combination of cyclical estrogen-progesterone treatment introduced after 1 to 2 years to initiate menstruation and to reduce the risk of future osteoporosis. SHRT can be interrupted once every 2 to 3 years, for a period of 6 months, to evaluate possible spontaneous recovery of ovarian activity, which occurs in a minority of women. Because of the high incidence of gonadal dysfunction and early menopause in patients after SCT, an annual clinical and biologic gynecologic assessment is recommended.

Fertility following stem cell transplantation

Despite the potential gonadotoxicity of pretransplantation conditioning (see “Puberty and gonadal failure”), gonadal recovery and pregnancies following SCT are well described (Tables 2 and3). The precise incidence of fertility following SCT is hard to establish. Unpublished data from the EBMT Late Effects Working Party (LEWP) pregnancy database relating to incidence of pregnancy in patients transplanted prior to 1994 who survived for a minimum of 2 years is given in Table 2. These data are not comparative because the patients within the groups were not age matched. Nonetheless, it is clear that the overall incidence of pregnancy is low (< 2%) except for patients transplanted for SAA and this is in accordance with the available literature. Such data are limited in their ability to accurately predict the likely return of fertility post-SCT, however, because many patients do not wish to become parents following the diagnosis of a potentially life-threatening illness.

Table 2.

Incidence of pregnancy following stem cell transplantation

FemaleMale
Survivors*Pregnancies n (%)Survivors*Pregnancies n (%)
Total 7615 113 (1.5) 10 467 119 (1.1) 
Allografts 3695 74 (2) 5 124 93 (1.8) 
Autografts 3920 39 (1) 5 343 26 (0.5)  
 Acute leukemia 2632 24 (0.9) 3 685 33 (0.9)  
 Chronic leukemia 1081 8 (0.7) 1 467 26 (1.8) 
 Lymphoma 1641 29 (1.8) 2 666 17 (0.6) 
 Aplastic anemia 385 47 (12.2) 605 32 (5.3) 
 Myeloma/amyloid 323 1 (0.3) 485 2 (0.4) 
 Other 1553 1 559 
FemaleMale
Survivors*Pregnancies n (%)Survivors*Pregnancies n (%)
Total 7615 113 (1.5) 10 467 119 (1.1) 
Allografts 3695 74 (2) 5 124 93 (1.8) 
Autografts 3920 39 (1) 5 343 26 (0.5)  
 Acute leukemia 2632 24 (0.9) 3 685 33 (0.9)  
 Chronic leukemia 1081 8 (0.7) 1 467 26 (1.8) 
 Lymphoma 1641 29 (1.8) 2 666 17 (0.6) 
 Aplastic anemia 385 47 (12.2) 605 32 (5.3) 
 Myeloma/amyloid 323 1 (0.3) 485 2 (0.4) 
 Other 1553 1 559 

Data from EBMT LEWP database.

*

The number of patients surviving more than 2 years following SCT.

Table 3.

Gonadal recovery following SCT

Type of SCTConditioningSexnGonadal recoveryReference
Allogeneic Cy 43 74% (100% < 26; 31% > 26) Spinelli et al133 
Allogeneic Cy 103 54% Sanders et al135 
Allogeneic Cy 109 61% Sanders et al135 
Allogeneic BuCy 73 1% Sanders et al135 
Allogeneic BuCy 146 17% Sanders et al135 
Allogeneic TBI 74 13.5% (100% < 18; 15% > 18) Bakker et al131 
Allogeneic TBI 532 10% Sanders et al138 
Allogeneic TBI 463 17.5%  Sanders et al138 
Autologous BEAM 10 60% Salooja et al139 
Autologous BEAM 13 Jacob et al140 
Autologous BEAM 10 Jackson et al141 
Type of SCTConditioningSexnGonadal recoveryReference
Allogeneic Cy 43 74% (100% < 26; 31% > 26) Spinelli et al133 
Allogeneic Cy 103 54% Sanders et al135 
Allogeneic Cy 109 61% Sanders et al135 
Allogeneic BuCy 73 1% Sanders et al135 
Allogeneic BuCy 146 17% Sanders et al135 
Allogeneic TBI 74 13.5% (100% < 18; 15% > 18) Bakker et al131 
Allogeneic TBI 532 10% Sanders et al138 
Allogeneic TBI 463 17.5%  Sanders et al138 
Autologous BEAM 10 60% Salooja et al139 
Autologous BEAM 13 Jacob et al140 
Autologous BEAM 10 Jackson et al141 

Other studies have looked at clinical and laboratory indicators of gonadal function in post-SCT patients. In women these include amenorrhea, menopausal symptoms, raised gonadotrophin levels, and low estrogen. In men, sperm quality (motility and morphology) and quantity can be assessed, and the typical biochemical profile would be raised FSH with normal LH and normal/low testosterone levels.

Fertility following SCT for nonmalignant disease

Return of gonadal function following cyclophosphamide conditioning for SAA was noted in 56 of 103 adult female survivors in Seattle (as indicated by return of menstruation and normal gonadotrophin and estradiol levels); 28 (27%) women subsequently conceived.138 Of 109 adult male survivors in the same study, 61% had return of sperm production and 28 (26%) subsequently fathered children. Previous data from this and from other centers indicated that gonadal recovery is usual in women younger than the age of 25 years at the time of transplantation but sharply decrease thereafter.135,142,143 In thalassemia, gonadal failure is common as a result of both transfusional hemosiderosis and conditioning with BuCy. Approximately 40% enter puberty, but pregnancies are very rare.144,145 

Fertility following SCT for malignant disease

Most of the patients given TBI conditioning experience gonadal failure. Recovery of gonadal function occurs in 10% to 14% of the women, and the incidence of pregnancy is less than 3%.133,138,139 In men, recovery of gonadal function has been reported in less than 20% of patients, and use of increasing doses of TBI may be associated with considerably lower recovery.138,140 Parenting a child following administration of TBI is a rare event in men. We have identified 27 men who fathered children naturally following TBI,139and 5 such patients have been reported by the Seattle group.138 

The use of busulphan and cyclophosphamide (BuCy) is also associated with a high incidence of gonadal failure in women, and there have been no pregnancies reported using BuCy for patients with leukemia.138,139 In men, this conditioning appears to be associated with return of gonadal function in approximately 17% of cases, which is similar to the recovery after TBI conditioning. Few patients have subsequently fathered children naturally; 20 patients were identified by the EBMT LEWP139 and 2 patients were reported by the Seattle group.138 Melphalan alone or associated with VP16 or cyclophosphamide in SCT conditioning is compatible with return of fertility in up to 50% of cases.141,146 

Fewer studies have evaluated gonadal function following autologous SCT, and most of these studies have involved small numbers of patients. The use of BEAM (bischolorethylnitrosourea, etoposide, ara-C, melphalan) conditioning for autografts may be associated with a high incidence of gonadal recovery in women,147 but in men azoospermia is almost always the rule.148,149 The EBMT LEWP has retrospectively identified 7 male patients who have fathered children naturally following BEAM, however.139 

Pretransplantation counseling and treatment options

Ideally, the pretransplantation counseling process should include data on the chance of gonadal failure and should assess the relevance of this situation to the patient. If the patient is of reproductive age and wishes to parent a child following SCT, it may be possible to alter the choice of conditioning protocol without compromising other factors such as survival. Clearly, this is not always an option, and discussion of management options for gonadal failure is thus essential. This should include discussion of assisted conception techniques and in women management of a premature menopause. In women with no residual ovarian function following SCT, implantation of embryos cryopreserved prior to SCT is currently the only option for parenting a woman's own genetic child. This option, however, requires that prior to SCT the underlying disease can tolerate a minimum 4- to 6-week delay in treatment for controlled stimulation of the ovary and egg collection. It also requires that the patient have a committed partner to provide sperm. In situations in which treatment cannot be delayed or there is no committed partner, consideration can be given to freezing ovarian tissue prior to SCT. Centers in some countries will provide this service for young women, but the patients need to be aware that currently this is a research rather than clinical tool and that to date there have been no successful pregnancies in human subjects using this methodology. Although the incidence of assisted conception increases annually, there are few published reports of pregnancy outcome following assisted conception in SC transplant recipients.150-152 In the pregnancy outcome study published by the EBMT LEWP, a high incidence of relapse was noted in female patients with chronic myelocytic leukemia (CML) who had conceived using assisted techniques.139 On this basis we recommended that women with CML who wish to have assisted conception wait for 2 years post-SCT and are demonstrated to be bcr-abl negative before implantation.

Sperm cryopreserved prior to SCT may be used post-SCT for artificial insemination, in vitro fertilization (IVF), and embryo transfer or for in vitro injection into the cytoplasm of the oocyte (ICSI). Semen collection should ideally occur at diagnosis before chemotherapy has been given. Concurrent administration of chemotherapy is not an absolute contraindication to storage, but the patient must be informed of potential risks.

Posttransplantation management should routinely include symptomatic and biochemical monitoring of gonadal function. Although the patient should be prepared for infertility, a possible need for contraception soon after SCT must also be emphasized, particularly in women who resume menstruation or patients who do not wish to become parents. Patients have conceived within 6 months of SCT, and unexpected pregnancy may result in requests for termination. Distressing vasomotor symptoms may commence acutely post-SCT, but this situation may be prevented by initiating SHRT. Alternatively, SHRT can be initiated at the onset of symptoms or when gonadotrophin levels indicate ovarian failure. SHRT does not suppress ovulation and will not, therefore, prevent recovery of gonadal function or pregnancy. It is, therefore, important to intermittently withdraw HRT and assess gonadotrophin levels. If there are signs of gonadal recovery, patients may benefit from contraceptive advice. Alternatively, because recovery in women is likely to be followed by a premature menopause, this period may be perceived by the patients as a window of opportunity to conceive naturally. Only regular follow-up will identify this point in time.

Quality of life and neuropsychological functioning

Quality of life (QoL) has become an essential outcome criterion for treatment strategies.153 QoL assessment can identify rehabilitation needs and can facilitate the initiation and evaluation of rehabilitation programs. When SCT is an alternative competing therapeutic option for a disease, eg, chronic myelogenous leukemia or acute myeloid leukemia, QoL may be integrated in the pre-SCT counseling, in an often-complex clinical decision-making process. Finally, psychosocial and QoL indices may have a predictive value for survival in SCT.154 

Despite a clear definition of health by the World Heath Organization in 1948, as a “ state of complete physical, mental and social well being, and not merely the absence of disease,” QoL remains difficult to measure. It can be considered to be a multidimensional, time-dependent concept, which is both individual and subjective. Furthermore, there is poor correlation between symptoms and signs and overall QoL. Self-evaluation by the patient rather than reporting by observers is thus of central importance when assessing QoL.

Two main approaches can be used for self-evaluation of QoL: (1) psychometric tests (questionnaires) and (2) utility/preferences measures. These approaches should include items concerning physical functioning, disease/treatment-related symptoms, psychological and social functioning, sexual functioning and body image, satisfaction with health care and the doctor-patient relationship, and, more recently, spiritual concerns. Psychometric measures can be generic, disease specific, and site or therapeutic specific. Many instruments have been developed, for example the Sickness Impact Profile (SIP)155 or SF-36156 for generic assessment and the European Organization for Research and Treatment of Cancer Core Quality of Life (EORTC QLQ-C30)157 or FACT158 (Functional Assessment of Cancer Therapy Scale) for cancer patients. For SCT patients, a specific questionnaire has been validated, the FACT-BMT.159 These instruments are patterned around a similar concept: a core questionnaire consisting of several subunits for specific life domains, in combination with disease- or treatment-specific modules. The psychometric measures provide a descriptive profile as to how each patient is feeling, and it can be used to describe groups of patients for comparative purposes in clinical trials. However, for decision making, it may be desirable to formally compare the therapeutic benefit versus the changes in QoL for a given clinical management strategy. For example, if the more efficacious therapy is associated with poorer QoL, is it worthwhile? Various methods are available for determining patients' preferences. The utility approach, combining survival and QoL (like quality adjusted time without symptoms or toxicity, Q-TWiST) enables a comparison of different policies of management when both survival and QoL vary simultaneously by combining QoL and survival into a single summary score. These tools have been mainly used in patients with cancer, but to date there has been only one published study160comparing patients who underwent SCT with patients treated by chemotherapy alone.

Overall, studies161,162 have reported good levels of function and well-being in long-term survivors of SCT. Despite this level of functioning, there are increased reports of fatigue, lack of energy, sleep problems, and sexual dissatisfaction. Risk factors identified for impaired QoL post-SCT include older age and advanced disease at SCT, lower level of education, and the development of cGVHD.

Fatigue and sleeping disorders have been reported in up to 65% patients post-SCT,154,163,164 and these changes may persist for several years following SCT.164-167 Problems with sexuality and intimacy after SCT are reported in approximately 25% of patients. Changes in sexual experience and lower level of sexual satisfaction have been reported in addition to disorders of sexual functioning.165,168-171 Some data suggest that women have higher prevalence rates than men.168,172Neuropsychological deficits have also been investigated in patients undergoing allogeneic SCT.173-175 Problems with memory can be found in nearly 20% of patients within the first year after SCT; this problem is unrelated to the patient's emotional status or intake of psychoactive drugs. However, neuropsychological examination prior to SCT also reveals cognitive impairments in 10% of patients.163,164,176 Patients with a history of central nervous system (CNS) disease seemed to be at higher risk of cognitive deficits, especially children treated with cranial radiation or the combination of cytotoxic drugs and irradiation.166,173-175,177-180 Lower IQ levels have been described in children 1 year following SCT, but this decrease remained stable at the 3-year follow-up.181 Changes in IQ were minimal, however, in children transplanted at a very young age (< 3 years).178 

Conclusion

Allogeneic SCT has been able to cure thousands of patients with otherwise lethal diseases. In this century our aim is not only to cure a patient's underlying disease but also to minimize the incidence of post-SCT complications and ensure the best possible QoL. The 2 main risk factors (pretransplantation conditioning and chronic GVHD) have hitherto been poorly amenable to modifications. The advent of reduced intensity conditioning for SCT and new immunosuppressive drugs will hopefully open the door for a curative procedure with relatively few late effects.

We realize that numerous reports and publications have not been included in the present review. We would like to express our excuses to authors not cited in the present manuscript because of lack of space (limited by Blood requirements for reviews).

Note from G.S.: while on the way to Seattle on September 11, 2001, my plane was obliged to land in Newfoundland (Canada), for obvious security reasons. The Memorial University of Newfoundland then hosted me for 6 days. The goal of my trip was a lecture on Late Effect after SCT. I would thus dedicate this review to Memorial University and the individuals who hosted me during those never-forgotten days.

members of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation

Gérard Socié (chairman), Hôpital St Louis, Paris, France; André Tichelli (secretary), University Hospitals, Basel, Switzerland; Jane Apperley, Hammersmith, London, United Kingdom; Mutlu Arat, Department of Hematology and BMT Unit, Ankara University Medical School, Turkey; Albert N. Békássy, Department of Pediatrics, University Hospital, Lund, Sweden; Dorine Bresters, Department of Pediatrics, Leiden University Hospital Center, the Netherlands; Enric Carreras, Hospital Clinic, Barcelona, Spain; Amnon Cohen, Department of Pediatrics, St Paul Hospital, Savona, Italy; Joerg Halter, University Hospital, Zürich, Switzerland; Jill Hows, Bristol, United Kingdom; Emin Kansu, Institute of Oncology, Hacettepe University, Ankara, Turkey; Alexander Kiss, University Hospitals, Basel, Switzerland; Elisabeth Korthof, Department of Pediatrics, Leiden University Hospital Center, the Netherlands; Hans-Jochem Kolb, Grosshadern, Muenchen, Germany; Anita Lawitschka, Department of Stem Cell Transplantation, St Anna Kinderspital, Vienna, Austria; Vincent Levy, DBIM, Hôpital St Louis, Paris, France; Per Ljungman, Huddinge University Hospital, Sweden; Anna Locasciulli, Ematologia, San Camillo Hospital, Roma, Italy; Shaun McCann, St James Hospital, Dublin, Ireland; Andreas Mumm, Klinik für Tumor-Biologie, Freiburg, Germany; Ann Nunn, Bristol, United Kingdom; Joan O'Riordan, St James Hospital, Dublin, Ireland; Jakob Passweg, University Hospitals, Basel, Switzerland; Christina Peters, Department of Stem Cell Transplantation, St Anna Kinderspital, Vienna, Austria; Michael Ranke, Tübingen, Germany; Attilio Rovelli, Pediatric Department, San Gerardo Hospital, Monza, Italy; Tapani Ruutu, Finland; Nina Salooja, Hammersmith, London, United Kingdom; Michael Schleuning, München, Germany; Hubert Schrezenmeier, Berlin, Germany; Philipp Schwarze, University Childrens Hospital, Tübingen, Germany; Cornelio Uderzo, Monza, Italy; Johanna Ullmann, Grosshadern, München, Germany; Elizabeth Vandenberghe, St James Hospital, Dublin, Ireland; Marie Louise van Kempen, Department of Radiotherapy, University Medical Center, Utrecht, the Netherlands; Maria Teresa Van-Lint, Centro trapianti ospedale San Martino, Genoa, Italy; Joachim Weis, Klinik für Tumor-Biologie, Freiburg, Germany; and Dorotea Wojcik, Department of Children's Hematology and Oncology, Wroclaw, Poland.

Prepublished online as Blood First Edition Paper, January 2, 2003; DOI 10.1182/blood-2002-07-2231.

A complete list of the members of the Late Effect Working Party of the European Group for Blood and Marrow Transplantation appears in the “.”

References

References
1
Kolb
HJ
Socie
G
Duell
T
et al
Malignant neoplasms in long-term survivors of bone marrow transplantation.
Ann Intern Med.
131
1999
738
744
2
Curtis
RE
Rowlings
PA
Deeg
HJ
et al
Solid cancers after bone marrow transplantation.
N Engl J Med.
336
1997
897
904
3
Deeg
HJ
Socie
G
Malignancies after hematopoietic stem cell transplantation: many questions, some answers.
Blood.
91
1998
1833
1844
4
Adès
L
Guardiola
P
Socie
G
Second malignancies after allogeneic stem cell transplantation: new insight and current problems.
Blood Rev.
16
2002
1
12
5
Duell
T
Vanlint
MT
Ljungman
P
et al
Health and functional status of long-term survivors of bone marrow transplantation.
Ann Intern Med.
126
1997
184
192
6
Vogelsang
GB
How I treat chronic graft-versus-host disease.
Blood.
97
2001
1196
1201
7
Sullivan
KM
Agura
E
Anasetti
C
et al
Chronic graft-versus-host disease and other late complications of bone marrow transplantation.
Semin Hematol.
28
1991
250
259
8
Akpek
G
Zahurak
ML
Piantadosi
S
et al
Development of a prognostic model for grading chronic graft-versus-host disease.
Blood.
97
2001
1219
1226
9
Vogelsang
GB
Hess
AD
Graft-versus-host disease: new directions for a persistent problem.
Blood.
84
1994
2061
2067
10
Flowers
ME
Parker
PM
Johnston
LJ
et al
Comparison of chronic graft-versus-host disease after transplantation of peripheral blood stem cells versus bone marrow in allogeneic recipients: long-term follow-up of a randomized trial.
Blood.
100
2002
415
419
11
Lee
SJ
Klein
JP
Barrett
AJ
et al
Severity of chronic graft-versus-host disease: association with treatment-related mortality and relapse.
Blood.
100
2002
406
414
12
Maury
S
Mary
JY
Rabian
C
et al
Prolonged immune deficiency following allogeneic stem cell transplantation: risk factors and complications in adult patients.
Br J Haematol.
115
2001
630
641
13
Small
TN
Papadopoulos
EB
Boulad
F
et al
Comparison of immune reconstitution after unrelated and related T-cell-depleted bone marrow transplantation: effect of patient age and donor leukocyte infusions.
Blood.
93
1999
467
480
14
Storek
J
Espino
G
Dawson
MA
et al
Low B-cell and monocyte counts on day 80 are associated with high infection rates between days 100 and 365 after allogeneic marrow transplantation.
Blood.
96
2000
3290
3293
15
Storek
J
Joseph
A
Espino
G
et al
Immunity of patients surviving 20 to 30 years after allogeneic or syngeneic bone marrow transplantation.
Blood.
98
2001
3505
3512
16
CDC IDSA ASBMT
Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients.
Biol Blood Marrow Transplant
6
6a
2000
659
741
17
Coskuncan
NM
Jabs
DA
Dunn
JP
et al
The eye in bone marrow transplantation, VI: retinal complications.
Arch Ophthalmol.
112
1994
372
379
18
Gratwohl
A
Gloor
B
Hahn
H
Speck
B
Retinal cotton-wool patches in bone-marrow-transplant recipients.
N Engl J Med.
308
1983
1101
19
Gloor
B
Gratwohl
A
Hahn
H
et al
Multiple cotton wool spots following bone marrow transplantation for treatment of acute lymphatic leukaemia.
Br J Ophthalmol.
69
1985
320
325
20
Bernauer
W
Gratwohl
A
Keller
A
Daicker
B
Microvasculopathy in the ocular fundus after bone marrow transplantation.
Ann Intern Med.
115
1991
925
930
21
Bylsma
GW
Hall
AJ
Szer
J
West
R
Atypical retinal microvasculopathy after bone marrow transplantation.
Clin Exp Ophthalmol.
29
2001
225
229
22
Lopez
PF
Sternberg
P
Jr
Dabbs
CK
et al
Bone marrow transplant retinopathy.
Am J Ophthalmol.
112
1991
635
646
23
O'Riordan
JM
FitzSimon
S
O'Connor
M
McCann
SR
Retinal microvascular changes following bone marrow transplantation: the role of cyclosporine.
Bone Marrow Transplant.
13
1994
101
104
24
Webster
AR
Anderson
JR
Richards
EM
Moore
AT
Ischaemic retinopathy occurring in patients receiving bone marrow allografts and campath-1G: a clinicopathological study.
Br J Ophthalmol.
79
1995
687
691
25
Lopez-Jimenez
J
Sanchez
A
Fernandez
CS
et al
Cyclosporine-induced retinal toxic blindness.
Bone Marrow Transplant.
20
1997
243
245
26
Deeg
HJ
Flournoy
N
Sullivan
KM
et al
Cataracts after total body irradiation and marrow transplantation: a sparing effect of dose fractionation.
Int J Radiat Oncol Biol Phys.
10
1984
957
964
27
Tichelli
A
Gratwohl
A
Egger
T
et al
Cataract formation after bone marrow transplantation.
Ann Intern Med.
119
1993
1175
1180
28
Benyunes
MC
Sullivan
KM
Deeg
HJ
et al
Cataracts after bone marrow transplantation: long-term follow-up of adults treated with fractionated total body irradiation.
Int J Radiat Oncol Biol Phys.
32
1995
661
670
29
Belkacemi
Y
Ozsahin
M
Pene
F
et al
Cataractogenesis after total body irradiation.
Int J Radiat Oncol Biol Phys.
35
1996
53
60
30
Belkacemi
Y
Labopin
M
Vernant
JP
et al
Cataracts after total body irradiation and bone marrow transplantation in patients with acute leukemia in complete remission: a study of the European Group for Blood and Marrow Transplantation.
Int J Radiat Oncol Biol Phys.
41
1998
659
668
31
Socie
G
Clift
RA
Blaise
D
et al
Busulfan plus cyclophosphamide compared with total-body irradiation plus cyclophosphamide before marrow transplantation for myeloid leukemia: long-term follow-up of 4 randomized studies.
Blood.
98
2001
3569
3574
32
Ozsahin
M
Belkacemi
Y
Pene
F
et al
Total-body irradiation and cataract incidence: a randomized comparison of two instantaneous dose rates.
Int J Radiat Oncol Biol Phys.
28
1994
343
347
33
Janin-Mercier
A
Devergie
A
Arrago
JP
et al
Systemic evaluation of Sjogren-like syndrome after bone marrow transplantation in man.
Transplantation.
43
1987
677
679
34
Jabs
DA
Wingard
J
Green
WR
et al
The eye in bone marrow transplantation, III: conjunctival graft-vs-host disease.
Arch Ophthalmol.
107
1989
1343
1348
35
Gratwohl
A
Moutsopoulos
HM
Chused
TM
et al
Sjogren-type syndrome after allogeneic bone-marrow transplantation.
Ann Intern Med.
87
1977
703
706
36
Arocker-Mettinger
E
Skorpik
F
Grabner
G
Hinterberger
W
Gadner
H
Manifestations of graft-versus-host disease following allogenic bone marrow transplantation.
Eur J Ophthalmol.
1
1991
28
32
37
Claes
K
Kestelyn
P
Ocular manifestations of graft versus host disease following bone marrow transplantation.
Bull Soc Belge Ophtalmol.
277
2000
21
26
38
Johnson
DA
Jabs
DA
The ocular manifestations of graft-versus-host disease.
Int Ophthalmol Clin.
37
1997
119
133
39
Ng
JS
Lam
DS
Li
CK
et al
Ocular complications of pediatric bone marrow transplantation.
Ophthalmology.
106
1999
160
164
40
Suh
DW
Ruttum
MS
Stuckenschneider
BJ
Mieler
WF
Kivlin
JD
Ocular findings after bone marrow transplantation in a pediatric population.
Ophthalmology.
106
1999
1564
1570
41
Tichelli
A
Duell
T
Weiss
M
et al
Late-onset keratoconjunctivitis sicca syndrome after bone marrow transplantation: incidence and risk factors. European Group or Blood and Marrow Transplantation (EBMT) Working Party on Late Effects.
Bone Marrow Transplant.
17
1996
1105
1111
42
Mencucci
R
Rossi
FC
Bosi
A
et al
Ophthalmological aspects in allogenic bone marrow transplantation: Sjogren-like syndrome in graft-versus-host disease.
Eur J Ophthalmol.
7
1997
13
18
43
Calissendorff
B
el Azazi
M
Lonnqvist
B
Dry eye syndrome in long-term follow-up of bone marrow transplanted patients.
Bone Marrow Transplant.
4
1989
675
678
44
Murphy
PT
Sivakumaran
M
Fahy
G
Hutchinson
RM
Successful use of topical retinoic acid in severe dry eye due to chronic graft-versus-host disease.
Bone Marrow Transplant.
18
1996
641
642
45
Soubani
AO
Miller
KB
Hassoun
PM
Pulmonary complications of bone marrow transplantation.
Chest.
109
1996
1066
1077
46
Cerveri
I
Fulgoni
P
Giorgiani
G
et al
Lung function abnormalities after bone marrow transplantation in children: has the trend recently changed?
Chest.
120
2001
1900
1906
47
Crawford
SW
Fisher
L
Predictive value of pulmonary function tests before marrow transplantation.
Chest.
101
1992
1257
1264
48
Ghalie
R
Szidon
JP
Thompson
L
et al
Evaluation of pulmonary complications after bone marrow transplantation: the role of pretransplant pulmonary function tests.
Bone Marrow Transplant.
10
1992
359
365
49
Jain
B
Floreani
AA
Anderson
JR
et al
Cardiopulmonary function and autologous bone marrow transplantation: results and predictive value for respiratory failure and mortality.
Bone Marrow Transplant.
17
1996
561
568
50
Carlson
K
Backlund
L
Smedmyr
B
Oberg
G
Simonsson
B
Pulmonary function and complications subsequent to autologous bone marrow transplantation.
Bone Marrow Transplant.
14
1994
805
811
51
Rovelli
A
Pezzini
C
Silvestri
D
et al
Cardiac and respiratory function after bone marrow transplantation in children with leukaemia.
Bone Marrow Transplant.
16
1995
571
576
52
Crawford
SW
Pepe
M
Lin
D
Benedetti
F
Deeg
HJ
Abnormalities of pulmonary function tests after marrow transplantation predict nonrelapse mortality.
Am J Respir Crit Care Med.
152
1995
690
695
53
Clark
JG
Crawford
SW
Madtes
DK
Sullivan
KM
Obstructive lung disease after allogeneic marrow transplantation: clinical presentation and course.
Ann Intern Med.
111
1989
368
376
54
Curtis
DJ
Smale
A
Thien
F
Schwarer
AP
Szer
J
Chronic airflow obstruction in long-term survivors of allogeneic bone marrow transplantation.
Bone Marrow Transplant.
16
1995
169
173
55
Schultz
KR
Green
GJ
Wensley
D
et al
Obstructive lung disease in children after allogeneic bone marrow transplantation.
Blood.
84
1994
3212
3220
56
Au
WY
Ho
JC
Lie
AK
et al
Respiratory ciliary function in bone marrow recipients.
Bone Marrow Transplant.
27
2001
1147
1151
57
Sargent
MA
Cairns
RA
Murdoch
MJ
et al
Obstructive lung disease in children after allogeneic bone marrow transplantation: evaluation with high-resolution CT.
AJR Am J Roentgenol.
164
1995
693
696
58
Chan
CK
Hyland
RH
Hutcheon
MA
et al
Small-airways disease in recipients of allogeneic bone marrow transplants: an analysis of 11 cases and a review of the literature.
Medicine (Baltimore).
66
1987
327
340
59
Holland
HK
Wingard
JR
Beschorner
WE
Saral
R
Santos
GW
Bronchiolitis obliterans in bone marrow transplantation and its relationship to chronic graft-v-host disease and low serum IgG.
Blood.
72
1988
621
627
60
Ralph
DD
Springmeyer
SC
Sullivan
KM
et al
Rapidly progressive air-flow obstruction in marrow transplant recipients: possible association between obliterative bronchiolitis and chronic graft-versus-host disease.
Am Rev Respir Dis.
129
1984
641
644
61
Sharples
LD
Tamm
M
McNeil
K
et al
Development of bronchiolitis obliterans syndrome in recipients of heart-lung transplantation—early risk factors.
Transplantation.
61
1996
560
566
62
Cooke
KR
Krenger
W
Hill
G
et al
Host reactive donor T cells are associated with lung injury after experimental allogeneic bone marrow transplantation.
Blood.
92
1998
2571
2580
63
Ooi
GC
Peh
WC
Ip
M
High-resolution computed tomography of bronchiolitis obliterans syndrome after bone marrow transplantation.
Respiration.
65
1998
187
191
64
Boas
SR
Noyes
BE
Kurland
G
Armitage
J
Orenstein
D
Pediatric lung transplantation for graft-versus-host disease following bone marrow transplantation.
Chest.
105
1994
1584
1586
65
Locasciulli
A
Nava
S
Sparano
P
Testa
M
Infections with hepatotropic viruses in children treated with allogeneic bone marrow transplantation.
Bone Marrow Transplant.
21
1998
S75
S77
66
Locasciulli
A
Alberti
A
de Bock
R
et al
Impact of liver disease and hepatitis infections on allogeneic bone marrow transplantation in Europe: a survey from the European Bone Marrow Transplantation (EBMT) Group—Infectious Diseases Working Party.
Bone Marrow Transplant.
14
1994
833
837
67
Locasciulli
A
Testa
M
Valsecchi
MG
et al
The role of hepatitis C and B virus infections as risk factors for severe liver complications following allogeneic BMT: a prospective study by the Infectious Disease Working Party of the European Blood and Marrow Transplantation Group.
Transplantation.
68
1999
1486
1491
68
Locasciulli
A
Testa
M
Valsecchi
MG
et al
Morbidity and mortality due to liver disease in children undergoing allogeneic bone marrow transplantation: a 10-year prospective study.
Blood.
90
1997
3799
3805
69
Ljungman
P
Johansson
N
Aschan
J
et al
Long-term effects of hepatitis C virus infection in allogeneic bone marrow transplant recipients.
Blood.
86
1995
1614
1618
70
Strasser
SI
Myerson
D
Spurgeon
CL
et al
Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up.
Hepatology.
29
1999
1893
1899
71
Strasser
SI
Sullivan
KM
Myerson
D
et al
Cirrhosis of the liver in long-term marrow transplant survivors.
Blood.
93
1999
3259
3266
72
Myers
RP
Swain
MG
Urbanski
SJ
Lee
SS
Reactivation of hepatitis B e antigen-negative chronic hepatitis B in a bone marrow transplant recipient following lamivudine withdrawal.
Can J Gastroenterol.
15
2001
599
603
73
Giardini
C
Galimberti
M
Lucarelli
G
et al
Alpha-interferon treatment of chronic hepatitis C after bone marrow transplantation for homozygous beta-thalassemia.
Bone Marrow Transplant.
20
1997
767
772
74
McKay
PJ
Murphy
JA
Cameron
S
et al
Iron overload and liver dysfunction after allogeneic or autologous bone marrow transplantation.
Bone Marrow Transplant.
17
1996
63
66
75
Iqbal
M
Creger
RJ
Fox
RM
et al
Laparoscopic liver biopsy to evaluate hepatic dysfunction in patients with hematologic malignancies: a useful tool to effect changes in management.
Bone Marrow Transplant.
17
1996
655
662
76
Strasser
SI
Kowdley
KV
Sale
GE
McDonald
GB
Iron overload in bone marrow transplant recipients.
Bone Marrow Transplant.
22
1998
167
173
77
Mariotti
E
Angelucci
E
Agostini
A
et al
Evaluation of cardiac status in iron-loaded thalassaemia patients following bone marrow transplantation: improvement in cardiac function during reduction in body iron burden.
Br J Haematol.
103
1998
916
921
78
Muretto
P
Del Fiasco
S
Angelucci
E
De Rosa
F
Lucarelli
G
Bone marrow transplantation in thalassemia: modifications of hepatic iron overload and associated lesions after long-term engrafting.
Liver.
14
1994
14
24
79
Bonkovsky
HL
Banner
BF
Rothman
AL
Iron and chronic viral hepatitis.
Hepatology.
25
1997
759
768
80
Maertens
J
Demuynck
H
Verbeken
EK
et al
Mucormycosis in allogeneic bone marrow transplant recipients: report of five cases and review of the role of iron overload in the pathogenesis.
Bone Marrow Transplant.
24
1999
307
312
81
de la Serna
J
Bornstein
R
Garcia-Bueno
MJ
Lahuerta-Palacios
JJ
Iron depletion by phlebotomy with recombinant erythropoietin prior to allogeneic transplantation to prevent liver toxicity.
Bone Marrow Transplant.
23
1999
95
97
82
Angelucci
E
Muretto
P
Lucarelli
G
et al
Phlebotomy to reduce iron overload in patients cured of thalassemia by bone marrow transplantation. Italian Cooperative Group for Phlebotomy Treatment of Transplanted Thalassemia Patients.
Blood.
90
1997
994
998
83
Atkinson
K
Cohen
M
Biggs
J
Avascular necrosis of the femoral head secondary to corticosteroid therapy for graft-versus-host disease after marrow transplantation: effective therapy with hip arthroplasty.
Bone Marrow Transplant.
2
1987
421
426
84
Enright
H
Haake
R
Weisdorf
D
Avascular necrosis of bone: a common serious complication of allogeneic bone marrow transplantation.
Am J Med.
89
1990
733
738
85
Socie
G
Cahn
JY
Carmelo
J
et al
Avascular necrosis of bone after allogeneic bone marrow transplantation: analysis of risk factors for 4388 patients by the Societe Francaise de Greffe de Moelle (SFGM).
Br J Haematol.
97
1997
865
870
86
Socie
G
Selimi
F
Sedel
L
et al
Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors.
Br J Haematol.
86
1994
624
628
87
Fink
JC
Leisenring
WM
Sullivan
KM
Sherrard
DJ
Weiss
NS
Avascular necrosis following bone marrow transplantation: a case-control study.
Bone.
22
1998
67
71
88
Bizot
P
Witvoet
J
Sedel
L
Avascular necrosis of the femoral head after allogenic bone-marrow transplantation—a retrospective study of 27 consecutive THAs with a minimal two-year follow-up.
J Bone Joint Surg Br.
78B
1996
878
883
89
Bizot
P
Nizard
R
Socie
G
et al
Femoral head osteonecrosis after bone marrow transplantation.
Clin Orthop.
357
1998
127
134
90
Marsh
JCW
Zomas
A
Hows
JM
Chapple
M
Gordonsmith
EC
Avascular necrosis after treatment of aplastic anaemia with antilymphocyte globulin and high-dose methylprednisolone.
Br J Haematol.
84
1993
731
735
91
Weilbaecher
KN
Mechanisms of osteoporosis after hematopoietic cell transplantation.
Biol Blood Marrow Transplant.
6
2000
165
174
92
Schimmer
AD
Minden
MD
Keating
A
Osteoporosis after blood and marrow transplantation: clinical aspects.
Biol Blood Marrow Transplant.
6
2000
175
181
93
Stern
JM
Sullivan
KM
Ott
SM
et al
Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.
Biol Blood Marrow Transplant.
7
2001
257
264
94
Socie
G
Mary
JY
Esperou
H
et al
Health and functional status of adult recipients 1 year after allogeneic haematopoietic stem cell transplantation.
Br J Haematol.
113
2001
194
201
95
Pajari
U
Lanning
M
Developmental defects of teeth in survivors of childhood ALL are related to the therapy and age at diagnosis.
Med Pediatr Oncol.
24
1995
310
314
96
Dahllof
G
Barr
M
Bolme
P
et al
Disturbances in dental development after total body irradiation in bone marrow transplant recipients.
Oral Surg Oral Med Oral Pathol.
65
1988
41
44
97
Valdez
IH
Patton
LL
Aplastic anemia: current concepts and dental management.
Spec Care Dentist.
10
1990
185
189
98
Heimdahl
A
Johnson
G
Danielsson
KH
et al
Oral condition of patients with leukemia and severe aplastic anemia: follow-up 1 year after bone marrow transplantation.
Oral Surg Oral Med Oral Pathol.
60
1985
498
504
99
Cole
BO
Welbury
RR
Bond
E
Abinun
M
Dental manifestations in severe combined immunodeficiency following bone marrow transplantation.
Bone Marrow Transplant.
25
2000
1007
1009
100
Uderzo
C
Fraschini
D
Balduzzi
A
et al
Long-term effects of bone marrow transplantation on dental status in children with leukaemia.
Bone Marrow Transplant.
20
1997
865
869
101
Sklar
CA
Kim
TH
Ramsay
NK
Thyroid dysfunction among long-term survivors of bone marrow transplantation.
Am J Med.
73
1982
688
694
102
Al Fiar
FZ
Colwill
R
Lipton
JH
et al
Abnormal thyroid stimulating hormone (TSH) levels in adults following allogeneic bone marrow transplants.
Bone Marrow Transplant.
19
1997
1019
1022
103
Boulad
F
Bromley
M
Black
P
et al
Thyroid dysfunction following bone marrow transplantation using hyperfractionated radiation.
Bone Marrow Transplant.
15
1995
71
76
104
Sanders
JE
Pritchard
S
Mahoney
P
et al
Growth and development following marrow transplantation for leukemia.
Blood.
68
1986
1129
1135
105
Katsanis
E
Shapiro
RS
Robison
LL
et al
Thyroid dysfunction following bone marrow transplantation: long-term follow-up of 80 pediatric patients.
Bone Marrow Transplant.
5
1990
335
340
106
Legault
L
Bonny
Y
Endocrine complications of bone marrow transplantation in children.
Pediatr Transplant.
3
1999
60
66
107
Cohen
A
Rovelli
A
Van Lint
MT
et al
Secondary thyroid carcinoma after allogeneic bone marrow transplantation during childhood.
Bone Marrow Transplant.
28
2001
1125
1128
108
Cohen
A
Is endocrinological assessment and follow-up of children after bone marrow transplantation necessary? How, and for how long?
Pediatr Transplant.
3
1999
1
4
109
Keilholz
U
Max
R
Scheibenbogen
C
et al
Endocrine function and bone metabolism 5 years after autologous bone marrow/blood-derived progenitor cell transplantation.
Cancer.
79
1997
1617
1622
110
Borgstrom
B
Bolme
P
Thyroid function in children after allogeneic bone marrow transplantation.
Bone Marrow Transplant.
13
1994
59
64
111
Toubert
ME
Socie
G
Gluckman
E
et al
Short- and long-term follow-up of thyroid dysfunction after allogeneic bone marrow transplantation without the use of preparative total body irradiation.
Br J Haematol.
98
1997
453
457
112
Aldouri
MA
Ruggier
R
Epstein
O
Prentice
HG
Adoptive transfer of hyperthyroidism and autoimmune thyroiditis following allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Br J Haematol.
74
1990
118
119
113
Berisso
GA
Van Lint
MT
Bacigalupo
A
Marmont
AM
Adoptive autoimmune hyperthyroidism following allogeneic stem cell transplantation from an HLA-identical sibling with Graves' disease.
Bone Marrow Transplant.
23
1999
1091
1092
114
Sanders
JE
The impact of marrow transplant preparative regimens on subsequent growth and development. The Seattle Marrow Transplant Team.
Semin Hematol.
28
1991
244
249
115
Cohen
A
Rovelli
A
Van Lint
MT
et al
Final height of patients who underwent bone marrow transplantation during childhood.
Arch Dis Child.
74
1996
437
440
116
Cohen
A
Rovelli
A
Bakker
B
et al
Final height of patients who underwent bone marrow transplantation for hematological disorders during childhood: a study by the Working Party for Late Effects-EBMT.
Blood.
93
1999
4109
4115
117
Cohen
A
Duell
T
Socie
G
et al
Nutritional status and growth after bone marrow transplantation (BMT) during childhood: EBMT Late-Effects Working Party retrospective data. European Group for Blood and Marrow Transplantation.
Bone Marrow Transplant.
23
1999
1043
1047
118
Huma
Z
Boulad
F
Black
P
Heller
G
Sklar
C
Growth in children after bone marrow transplantation for acute leukemia.
Blood.
86
1995
819
824
119
Michel
G
Socie
G
Gebhard
F
et al
Late effects of allogeneic bone marrow transplantation for children with acute myeloblastic leukemia in first complete remission: the impact of conditioning regimen without total-body irradiation—a report from the Societe Francaise de Greffe de Moelle.
J Clin Oncol.
15
1997
2238
2246
120
Clement-De Boers
A
Oostdijk
W
Weel-Sipman
MH
et al
Final height and hormonal function after bone marrow transplantation in children.
J Pediatr.
129
1996
544
550
121
Shinagawa
T
Tomita
Y
Ishiguro
H
et al
Final height and growth hormone secretion after bone marrow transplantation in children.
Endocr J.
48
2001
133
138
122
Shinohara
O
Kato
S
Yabe
H
et al
Growth after bone marrow transplantation in children.
Am J Pediatr Hematol Oncol.
13
1991
263
268
123
Couto-Silva
AC
Trivin
C
Esperou
H
et al
Changes in height, weight and plasma leptin after bone marrow transplantation.
Bone Marrow Transplant.
26
2000
1205
1210
124
Sklar
C
Mertens
A
Walter
A
et al
Final height after treatment for childhood acute lymphoblastic leukemia: comparison of no cranial irradiation with 1800 and 2400 centigrays of cranial irradiation.
J Pediatr.
123
1993
59
64
125
Giorgiani
G
Bozzola
M
Locatelli
F
et al
Role of busulfan and total body irradiation on growth of prepubertal children receiving bone marrow transplantation and results of treatment with recombinant human growth hormone.
Blood.
86
1995
825
831
126
Hovi
L
Rajantie
J
Perkkio
M
et al
Growth failure and growth hormone deficiency in children after bone marrow transplantation for leukemia.
Bone Marrow Transplant.
5
1990
183
186
127
Brauner
R
Adan
L
Souberbielle
JC
et al
Contribution of growth hormone deficiency to the growth failure that follows bone marrow transplantation.
J Pediatr.
130
1997
785
792
128
Kauppila
M
Koskinen
P
Irjala
K
Remes
K
Viikari
J
Long-term effects of allogeneic bone marrow transplantation (BMT) on pituitary, gonad, thyroid and adrenal function in adults.
Bone Marrow Transplant.
22
1998
331
337
129
Mertens
AC
Ramsay
NK
Kouris
S
Neglia
JP
Patterns of gonadal dysfunction following bone marrow transplantation.
Bone Marrow Transplant.
22
1998
345
350
130
Uruena
M
Stanhope
R
Chessells
JM
Leiper
AD
Impaired pubertal growth in acute lymphoblastic leukaemia.
Arch Dis Child.
66
1991
1403
1407
131
Bakker
B
Massa
GG
Oostdijk
W
et al
Pubertal development and growth after total-body irradiation and bone marrow transplantation for haematological malignancies.
Eur J Pediatr.
159
2000
31
37
132
Sarafoglou
K
Boulad
F
Gillio
A
Sklar
C
Gonadal function after bone marrow transplantation for acute leukemia during childhood.
J Pediatr.
130
1997
210
216
133
Spinelli
S
Chiodi
S
Bacigalupo
A
et al
Ovarian recovery after total body irradiation and allogeneic bone marrow transplantation: long-term follow up of 79 females.
Bone Marrow Transplant.
14
1994
373
380
134
Matsumoto
M
Shinohara
O
Ishiguro
H
et al
Ovarian function after bone marrow transplantation performed before menarche.
Arch Dis Child.
80
1999
452
454
135
Sanders
JE
Buckner
CD
Amos
D
et al
Ovarian function following marrow transplantation for aplastic anemia or leukemia.
J Clin Oncol.
6
1988
813
818
136
Afify
Z
Shaw
PJ
Clavano-Harding
A
Cowell
CT
Growth and endocrine function in children with acute myeloid leukaemia after bone marrow transplantation using busulfan/cyclophosphamide.
Bone Marrow Transplant.
25
2000
1087
1092
137
Thibaud
E
Rodriguez-Macias
K
Trivin
C
et al
Ovarian function after bone marrow transplantation during childhood.
Bone Marrow Transplant.
21
1998
287
290
138
Sanders
JE
Hawley
J
Levy
W
et al
Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation.
Blood.
87
1996
3045
3052
139
Salooja
N
Szydlo
RM
Socie
G
et al
Pregnancy outcomes after peripheral blood or bone marrow transplantation: a retrospective survey.
Lancet.
358
2001
271
276
140
Jacob
A
Goodman
A
Holmes
J
Fertility after bone marrow transplantation following conditioning with cyclophosphamide and total body irradiation.
Bone Marrow Transplant.
15
1995
483
484
141
Jackson
GH
Wood
A
Taylor
PR
et al
Early high dose chemotherapy intensification with autologous bone marrow transplantation in lymphoma associated with retention of fertility and normal pregnancies in females. Scotland and Newcastle Lymphoma Group, UK.
Leuk Lymphoma.
28
1997
127
132
142
Schmidt
H
Ehninger
G
Dopfer
R
Waller
HD
Pregnancy after bone marrow transplantation for severe aplastic anemia.
Bone Marrow Transplant.
2
1987
329
332
143
Hinterberger-Fischer
M
Kier
P
Kalhs
P
et al
Fertility, pregnancies and offspring complications after bone marrow transplantation.
Bone Marrow Transplant.
7
1991
5
9
144
De Sanctis
V
Galimberti
M
Lucarelli
G
et al
Gonadal function after allogenic bone marrow transplantation for thalassaemia.
Arch Dis Child.
66
1991
517
520
145
Borgna-Pignatti
C
Marradi
P
Rugolotto
S
Marcolongo
A
Successful pregnancy after bone marrow transplantation for thalassaemia.
Bone Marrow Transplant.
18
1996
235
236
146
Singhal
S
Powles
R
Treleaven
J
et al
Melphalan alone prior to allogeneic bone marrow transplantation from HLA-identical sibling donors for hematologic malignancies: alloengraftment with potential preservation of fertility in women.
Bone Marrow Transplant.
18
1996
1049
1055
147
Salooja
N
Chatterjee
R
McMillan
AK
et al
Successful pregnancies in women following single autotransplant for acute myeloid leukemia with a chemotherapy ablation protocol.
Bone Marrow Transplant.
13
1994
431
435
148
Chatterjee
R
Mills
W
Katz
M
McGarrigle
HH
Goldstone
AH
Germ cell failure and Leydig cell insufficiency in post-pubertal males after autologous bone marrow transplantation with BEAM for lymphoma.
Bone Marrow Transplant.
13
1994
519
522
149
Jacob
A
Barker
H
Goodman
A
Holmes
J
Recovery of spermatogenesis following bone marrow transplantation.
Bone Marrow Transplant.
22
1998
277
279
150
Rio
B
Letur-Konirsch
H
Ajchenbaum-Cymbalista
F
et al
Full-term pregnancy with embryos from donated oocytes in a 36-year-old woman allografted for chronic myeloid leukemia.
Bone Marrow Transplant.
13
1994
487
488
151
Lee
S
Ghalie
R
Kaizer
H
Sauer
MV
Successful pregnancy in a bone marrow transplant recipient following oocyte donation.
J Assist Reprod Genet.
12
1995
294
296
152
Atkinson
HG
Apperley
JF
Dawson
K
Goldman
JM
Winston
RM
Successful pregnancy after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lancet.
344
1994
199
153
Neitzert
CS
Ritvo
P
Dancey
J
et al
The psychosocial impact of bone marrow transplantation: a review of the literature.
Bone Marrow Transplant.
22
1998
409
422
154
McQuellon
RP
Russell
GB
Rambo
TD
et al
Quality of life and psychological distress of bone marrow transplant recipients: the ‘time trajectory’ to recovery over the first year.
Bone Marrow Transplant.
21
1998
477
486
155
Bergner
M
Bobbitt
RA
Carter
WB
Gilson
BS
The Sickness Impact Profile: development and final revision of a health status measure.
Med Care.
19
1981
787
805
156
Ware
JE
Jr
Sherbourne
CD
The MOS 36-item short-form health survey (SF-36), I: conceptual framework and item selection.
Med Care.
30
1992
473
483
157
Aaronson
NK
Ahmedzai
S
Bergman
B
et al
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.
J Natl Cancer Inst.
85
1993
365
376
158
Cella
DF
Tulsky
DS
Gray
G
et al
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.
J Clin Oncol.
11
1993
570
579
159
McQuellon
RP
Russell
GB
Cella
DF
et al
Quality of life measurement in bone marrow transplantation: development of the Functional Assessment of Cancer Therapy-Bone Marrow Transplant (FACT-BMT) scale.
Bone Marrow Transplant.
19
1997
357
368
160
Parsons
SK
Gelber
S
Cole
BF
et al
Quality-adjusted survival after treatment for acute myeloid leukemia in childhood: a Q-TWiST analysis of the Pediatric Oncology Group Study 8821.
J Clin Oncol.
17
1999
2144
2152
161
Sutherland
HJ
Fyles
GM
Adams
G
et al
Quality of life following bone marrow transplantation: a comparison of patient reports with population norms.
Bone Marrow Transplant.
19
1997
1129
1136
162
Heinonen
H
Volin
L
Uutela
A
et al
Gender-associated differences in the quality of life after allogeneic BMT.
Bone Marrow Transplant.
28
2001
503
509
163
Andrykowski
MA
Henslee
PJ
Barnett
RL
Longitudinal assessment of psychosocial functioning of adult survivors of allogeneic bone marrow transplantation.
Bone Marrow Transplant.
4
1989
505
509
164
Andrykowski
MA
Schmitt
FA
Gregg
ME
et al
Neuropsychologic impairment in adult bone marrow transplant candidates.
Cancer.
70
1992
2288
2297
165
Bush
NE
Donaldson
GW
Haberman
MH
Dacanay
R
Sullivan
KM
Conditional and unconditional estimation of multidimensional quality of life after hematopoietic stem cell transplantation: a longitudinal follow-up of 415 patients.
Biol Blood Marrow Transplant.
6
2000
576
591
166
Ahles
TA
Tope
DM
Furstenberg
C
Hann
D
Mills
L
Psychologic and neuropsychologic impact of autologous bone marrow transplantation.
J Clin Oncol.
14
1996
1457
1462
167
Knobel
H
Loge
JH
Nordoy
T
et al
High level of fatigue in lymphoma patients treated with high dose therapy.
J Pain Symptom Manage.
19
2000
446
456
168
Syrjala
KL
Roth-Roemer
SL
Abrams
JR
et al
Prevalence and predictors of sexual dysfunction in long-term survivors of marrow transplantation.
J Clin Oncol.
16
1998
3148
3157
169
Syrjala
KL
Chapko
MK
Vitaliano
PP
Cummings
C
Sullivan
KM
Recovery after allogeneic marrow transplantation: prospective study of predictors of long-term physical and psychosocial functioning.
Bone Marrow Transplant.
11
1993
319
327
170
Mumma
GH
Mashberg
D
Lesko
LM
Long-term psychosexual adjustment of acute leukemia survivors: impact of marrow transplantation versus conventional chemotherapy.
Gen Hosp Psychiatry.
14
1992
43
55
171
Baker
F
Wingard
JR
Curbow
B
et al
Quality of life of bone marrow transplant long-term survivors.
Bone Marrow Transplant.
13
1994
589
596
172
Hensel
M
Egerer
G
Schneeweiss
A
Goldschmidt
H
Ho
AD
Quality of life and rehabilitation in social and professional life after autologous stem cell transplantation.
Ann Oncol.
13
2002
209
217
173
Cool
VA
Long-term neuropsychological risks in pediatric bone marrow transplant: what do we know?
Bone Marrow Transplant.
18
1996
S45
S49
174
Thuret
I
Michel
G
Carla
H
et al
Long-term side-effects in children receiving allogeneic bone marrow transplantation in first complete remission of acute leukaemia.
Bone Marrow Transplant.
15
1995
337
341
175
Smedler
AC
Nilsson
C
Bolme
P
Total body irradiation: a neuropsychological risk factor in pediatric bone marrow transplant recipients.
Acta Paediatr.
84
1995
325
330
176
Meyers
CA
Weitzner
M
Byrne
K
et al
Evaluation of the neurobehavioral functioning of patients before, during, and after bone marrow transplantation.
J Clin Oncol.
12
1994
820
826
177
Padovan
CS
Yousry
TA
Schleuning
M
et al
Neurological and neuroradiological findings in long-term survivors of allogeneic bone marrow transplantation.
Ann Neurol.
43
1998
627
633
178
Phipps
S
Dunavant
M
Srivastava
DK
Bowman
L
Mulhern
RK
Cognitive and academic functioning in survivors of pediatric bone marrow transplantation.
J Clin Oncol.
18
2000
1004
1011
179
Arvidson
J
Kihlgren
M
Hall
C
Lonnerholm
G
Neuropsychological functioning after treatment for hematological malignancies in childhood, including autologous bone marrow transplantation.
Pediatr Hematol Oncol.
16
1999
9
21
180
Smedler
AC
Ringden
K
Bergman
H
Bolme
P
Sensory-motor and cognitive functioning in children who have undergone bone marrow transplantation.
Acta Paediatr Scand.
79
1990
613
621
181
Kramer
JH
Crittenden
MR
Halberg
FE
Wara
WM
Cowan
MJ
A prospective study of cognitive functioning following low-dose cranial radiation for bone marrow transplantation.
Pediatrics.
90
1992
447
450

Author notes

Gérard Socié, Service d'Hématologie/Greffe de Moelle, Hôpital Saint Louis AP-HP, 1 avenue Claude Vellefaux, 75475, Paris CEDEX 10, France; e-mail:gsocie@chu-stlouis.fr.